케모맵 테라퓨틱스(CMMB)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.61 (-6.79%), 시가총액 $0.01B, 52주 최저~최고 $0.87 ~ $3.50.
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
케모맵 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
케모맵 테라퓨틱스의 현재 주가는 $2.61 (-6.79%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
케모맵 테라퓨틱스의 시가총액은 약 $0.01B입니다.
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product c